Publicaciones en colaboración con investigadores/as de University of Bologna (7)

2024

  1. Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update

    Blood, Vol. 143, Núm. 17, pp. 1713-1725

  2. Rearrangements involving 11q23.3/KMT2A in adult AML: mutational landscape and prognostic implications – a HARMONY study

    Leukemia, Vol. 38, Núm. 9, pp. 1929-1937

2022

  1. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial

    Nature Medicine, Vol. 28, Núm. 2, pp. 325-332

2016

  1. Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low‐dose dexamethasone versus high‐dose dexamethasone in refractory or relapsed and refractory multiple myeloma

    Haematologica, Vol. 101, Núm. 7, pp. 872-878

2015

  1. Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone

    Haematologica, Vol. 100, Núm. 10, pp. 1327-1333

  2. Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma

    Haematologica, Vol. 100, Núm. 10, pp. 1334-1339

2013

  1. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): A randomised, open-label, phase 3 trial

    The Lancet Oncology, Vol. 14, Núm. 11, pp. 1055-1066